Sensei Biotherapeutics, Inc., a clinical-stage immunotherapy company, engages in the discovery and development of therapies with an initial focus on treatments for cancer. The company develops proprietary ImmunoPhage platform, an immunotherapy approach that is designed to utilize bacteriophage to induce a focused and coordinated innate and adaptive immune response. It is engineering ImmunoPhage product candidates to directly target antigen presenting cells and modulate the tumor microenvironment through the targeted use of nanobodies which further enhances therapeutic activity. Sensei Biotherapeutics, Inc. was formerly known as Panacea Pharmaceuticals, Inc. The company was founded in 1999 and is headquartered in Rockville, Maryland.
IPO Year: 2021
Exchange: NASDAQ
Website: senseibio.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/14/2024 | $5.00 | Overweight | Stephens |
| 3/10/2022 | $12.00 → $10.00 | Overweight | Piper Sandler |
| 7/1/2021 | $12.00 | Buy → Hold | Berenberg |
| 6/29/2021 | $30.00 → $14.00 | Outperform → Perform | Oppenheimer |
| 6/29/2021 | Outperform → Perform | Oppenheimer |
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
4 - Sensei Biotherapeutics, Inc. (0001829802) (Issuer)
BOSTON, March 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer, today announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement (the "Rights Agreement") to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make i
- SNS-101 identified as a tumor-selective anti-VISTA antibody product candidate from TMAb platform - - SNS-101 preclinical data accepted for presentation at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting; abstract available online in the Journal for ImmunoTherapy of Cancer - VISTA science symposium to be webcast Tuesday, November 16 at 4:00 p.m. ET – - Ended third quarter 2021 with cash, cash equivalents and marketable securities of 156.7 million; company reiterated cash runway at least into first half 2024 BOSTON, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next
- Company announced first set of pH-sensitive anti-VISTA antibodies showing significant in vivo anti-tumor activity in combination with PD-1 blockade in a human VISTA knock-in mouse model – - Company plans to select a lead SNS-VISTA candidate and initiate IND-enabling studies by year-end 2021 - SNS-401-NG on track to start IND-enabling studies in second half of 2022 – -Strong cash position of $162.5 million to support platform innovation and next generation program development - BOSTON, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reporte
- Favorable clinical data in PD-(L)1 resistant patients - - Dose expansion enrollment complete with full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter 2025, and provided corporate updates. "This was a breakthrough quarter for Sensei," said John Celebi, President and CEO. "We observed favorable signs of clinical activity in patients with PD-(L)1-resistant cancers from our dose expansi
BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will participate in the New Radiotherapy and Targeted Therapy Approaches panel at the Canaccord Genuity Horizons in Oncology Virtual Conference on Monday, April 7 at 2:00 p.m. ET. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tum
- Preliminary efficacy data from Phase 1/2 dose expansion cohort show durable responses and tumor shrinkage in a PD-(L)1 resistant "hot" tumor patient population - - Solnerstotug continues to demonstrate a well-tolerated safety and tolerability profile - - Achieved target enrollment in dose expansion cohort; full data expected by year-end 2025 - - Cash runway into the second quarter of 2026 - BOSTON, March 28, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full year 2024, and
– Initial clinical activity in a PD-(L)1 resistant population, with an ORR almost three times higher than historical PD-(L)1 rechallenge response rates, with data still maturing – – One durable complete response in a Merkel Cell Carcinoma (MCC) patient and two partial responses (PR), including one in a second MCC patient and one in a microsatellite instability-high (MSI-H) Colorectal Cancer (CRC) patient, all of whom were previously treated with and progressed on immunotherapy – – All PD-(L)1 resistant "hot" tumor patients with tumor shrinkage remain on study, suggesting potential for deepening responses over time – – Sensei to host investor webcast today at 5:30 p.m. ET – BOSTON, March
BOSTON, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that John Celebi, President and Chief Executive Officer, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, being held virtually, on Tuesday, February 11, 2025 at 10:40 a.m. ET. A webcast of Sensei's presentation will be available in the Investors section of the Sensei website. A replay of the webcast will be on the website for approximately 90 days following the event. Registration for the webcast is available here. About Sens
- Solnerstotug (SNS-101) dose expansion arm anticipated to be fully enrolled by end of Q1 2025 - - Clinical data update expected in Q2 2025 - BOSTON, Jan. 08, 2025 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (SNS-101) and upcoming milestones. "2024 was a noteworthy year for Sensei and our pioneering lead program, solnerstotug. We demonstrated that solnerstotug can overcome the safety and pharmacological hurdles associated with first-generation antibodies targeting the i
BOSTON, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will participate in Citi's 2024 Global Healthcare Conference, being held on December 3-5, in Miami, FL. About Sensei Biotherapeutics Sensei Biotherapeutics (NASDAQ:SNSE) is a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb™ (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro
BOSTON, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that the Company will present at two upcoming scientific conferences. Conference and Presentation Details: PEGS Europe: Protein and Antibody Engineering Summit, November 5-7, 2024, Barcelona, Spain Title: Selectively Targeting VISTA in the Tumor-Microenvironment with SNS-101, a Conditionally Active Monoclonal Antibody Presenter: Edward van der Horst, Ph.D., Chief Scientific Officer Session: Antibody-Based Cancer TherapiesDate and time: Tuesday, November 5, 2024, 9:00 a
BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that preclinical data on SNS-103 will be presented in a poster session at the CRI-ENCI Eighth International Immunotherapy Conference, being held September 8-11, 2024, at the Gaylord National Resort & Convention Center in National Harbor, MD. Presentation Details: CRI-ENCI Eighth International Cancer Immunotherapy Conference Title: Pre-clinical characterization of monoclonal antibodies targeting CD39 activity in the acidic tumor microenvironmentPresenter
Stephens initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $5.00
Piper Sandler reiterated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $10.00 from $12.00 previously
Berenberg downgraded Sensei Biotherapeutics from Buy to Hold and set a new price target of $12.00
Oppenheimer downgraded Sensei Biotherapeutics from Outperform to Perform and set a new price target of $14.00 from $30.00 previously
Oppenheimer downgraded Sensei Biotherapeutics from Outperform to Perform
Piper Sandler initiated coverage of Sensei Biotherapeutics with a rating of Overweight and set a new price target of $25.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform and set a new price target of $36.00
Oppenheimer initiated coverage of Sensei Biotherapeutics with a rating of Outperform
Berenberg Bank initiated coverage of Sensei Biotherapeutics with a rating of Buy and set a new price target of $27.00
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13G/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
SC 13D/A - Sensei Biotherapeutics, Inc. (0001829802) (Subject)
10-Q - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
DEFA14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
DEF 14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
PRE 14A - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
S-8 - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
10-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
8-K - Sensei Biotherapeutics, Inc. (0001829802) (Filer)
- SNS-101 Phase 1/2 dose expansion clinical data expected in the first half of 2025 - - Organizational restructuring to focus resources on advancing the clinical development of SNS-101 - - Cash runway extended into the second quarter of 2026 - BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third quarter ended September 30, 2024, and provided corporate updates. "The third quarter of 2024 saw significant progress in advancing patient enro
- Promising Phase 1/2 SNS-101 clinical data presented at ASCO 2024 - - Enrollment in the Phase 1 dose expansion of SNS-101 clinical trial advancing with initial data on track for Q4 2024 - - Strong balance sheet with cash runway into the fourth quarter of 2025 - BOSTON, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the second quarter ended June 30, 2024, and provided corporate updates. "Collectively, the clinical data presented on SNS-101 over the past six month
- Completed SNS-101 monotherapy and combination dose escalation through 15mg/kg with no dose limiting toxicities - - Company to present topline clinical data from the SNS-101 Phase 1 dose escalation study at the 2024 ASCO Annual Meeting - - Enrollment in the dose expansion portion of the clinical study advancing - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the first quarter ended March 31, 2024, and provide
- Updated dose escalation data from SNS-101 clinical study supports favorable and potentially best-in-class safety and PK profile both as monotherapy and in combination with PD-1 blockade - - Topline efficacy and biomarker data for both monotherapy and combination arms of dose escalation study now expected in Q2 2024, ahead of previous guidance - - Strong balance sheet with cash runway into fourth quarter of 2025 - BOSTON, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the full ye
- SNS-101 initial Phase 1 clinical data presented at SITC demonstrate potential best-in-class safety and pharmacokinetic profile, with no cytokine release syndrome or dose-limiting toxicities reported - - Phase 1/2 trial of SNS-101 continues to enroll ahead of schedule, with new clinical data milestones anticipated throughout 2024 - - Strong balance sheet with cash runway into the second half of 2025 - BOSTON, Nov. 07, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today reported financial results for the third qua
BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced the appointment of Stephanie Krebs, MS, MBA, as Chief Business Officer. Ms. Krebs joins Sensei from SNIPR Biome, a clinical-stage biotechnology company where, as Chief Business Officer, she was responsible for defining the company's growth and partnering activities, including value creation through collaborations with large pharmaceutical and biotech partners. Prior to this, she held business and corporate development roles of increasing responsibility i
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of Patrick Gallagher, MBA, MPH, as chief business officer. "Patrick is an accomplished biotech executive who brings significant strategic and transactional expertise to Sensei. He has worked across the biotechnology, Big Pharma, venture and banking sectors and has a track record of tailoring partnerships and transactions to build value," said John Celebi, president and chief executive officer of Sensei Biotherapeutics. "We're thrilled to add him to our leadership
- SNS-101 preclinical data provide encouraging validation of pH-sensitive approach to inhibiting VISTA with high selectivity to treat solid tumors - - Cash runway extended into the first quarter of 2025 with $136.2 million on hand at end of first quarter 2022 - BOSTON, May 10, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today reported financial results for the first quarter ended March 31, 2022, and provided recent corporate updates. "We continue to make significant progress in the development of our TMAb™ platform, which is designed to address the chall
BOSTON, March 09, 2022 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), an immunotherapy company focused on the discovery and development of next-generation therapeutics for cancer, today announced the appointment of William (Bill) Ringo, MBA, as chair of its Board of Directors. "Bill is an accomplished life sciences leader who has been instrumental to the success of multiple pharmaceutical companies and biotechs. His experience and insights will be invaluable to us as we advance our business objectives and pipeline of potentially transformative oncology therapeutics," said John Celebi, president and chief executive officer of Sensei Biotherapeutics. "We're delighted to hav
BOSTON and ROCKVILLE, Md., May 05, 2021 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (NASDAQ:SNSE), a clinical-stage immunotherapy company focused on the discovery and development of next generation therapeutics for cancer, today announced the appointments of Maura Gillison, M.D., Ph.D., Professor of Medicine, Thoracic/Head and Neck Medical Oncology at MD Anderson Cancer Center, and Richard Ulevitch, Ph.D., Professor of Immunology and Chairman Emeritus at The Scripps Research Institute, to its Immuno-Oncology Advisory Board. "We are honored to welcome both Dr. Gillison and Dr. Ulevitch to our Immuno-Oncology Advisory Board, two astounding leaders in the field of oncology and immuno